Plasminogen activator inhibitor-1 deficiency ameliorates insulin resistance and hyperlipidemia but not bone loss in obese female mice

Endocrinology

Volumn 155, Issue 5, 2014, Pages 1708-1717

  Tamura, Yukinori ^a   Kawao, Naoyuki ^a   Yano, Masato ^a   Okada, Kiyotaka ^a   Matsuo, Osamu ^a   Kaji, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CHOLESTEROL; GLUCOSE; INSULIN; LIGAND; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR OSTERIX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; BONE STRENGTH INDEX; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIET; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HIGH SUCROSE DIET; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; LIPID METABOLISM; METABOLIC PARAMETERS; MOUSE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; OBESITY; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TIBIA; TRABECULAR BONE; WILD TYPE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CHOLESTEROL; DIET, HIGH-FAT; DIETARY SUCROSE; FEMALE; GLUCOSE INTOLERANCE; HEMORRHAGIC DISORDERS; HYPERLIPIDEMIAS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84899444073     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1888     Document Type: Article

References (50)

1. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008;473(2):201-209.
2. Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010;11(4):219-227.
3. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007; 13(7):791-801.
4. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 2007;18(4):427-444.
5. Chen HF, Ho CA, Li CY. Increased risks of hip fracture in diabetic patients of Taiwan: a population-based study. Diabetes Care. 2008; 31(1):75-80.
6. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent ofBMDor diabetic complications. J Bone Miner Res. 2009; 24(4):702-709.
7. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22(9):1317-1328.
8. Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R. Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis. 2010;20(9):683-690.
9. Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes. 2011;2(3):41-48.
10. Inaba M. Secondary osteoporosis: thyrotoxicosis, rheumatoid arthritis, and diabetes mellitus. J Bone Miner Metab. 2004;22(4):287-292.
11. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59(7):635-643.
12. Gómez-Ambrosi J, Rodríguez A, Catalán V, Frühbeck G. The boneadipose axis in obesity and weight loss. Obes Surg. 2008;18(9): 1134-1143.
13. NielsonCM,Srikanth P, Orwoll ES. Obesity and fracture inmenand women: an epidemiologic perspective. J Bone Miner Res. 2012; 27(1):1-10.
14. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb. 2010;17(4):332-341.
15. Conde J, Scotece M, Gómez R, et al. Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors. 2011;37(6):413-420.
16. Tamura Y, Kawao N, Okada K, et al. Plasminogen activator inhibitor- 1 is involved in streptozotocin-induced bone loss in female mice. Diabetes. 2013;62(9):3170-3179.
17. Carmeliet P,MoonsL, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 1997;96(9):3180-3191.
18. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280(21):1843-1848.
19. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008; 117(13):1658-1667.
20. Gilsanz V, Chalfant J, Mo AO, Lee DC, Dorey FJ, Mittelman SD. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab. 2009;94(9):3387-3393.
21. von Muhlen D, Safii S, Jassal SK, Svartberg J, Barrett-Connor E. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int. 2007;18(10):1337-1344.
22. Goulding A, Taylor RW, Jones IE, McAuley KA, Manning PJ, Williams SM. Overweight and obese children have low bone mass and area for their weight. Int J Obes Relat Metab Disord. 2000;24(5): 627-632.
23. Blum M, Harris SS, Must A, et al. Leptin, body composition and bone mineral density in premenopausal women. Calcif Tissue Int. 2003;73(1):27-32.
24. Hsu YH, Venners SA, Terwedow HA, et al. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr. 2006;83(1):146-154.
25. Pollock NK, Laing EM, Baile CA, Hamrick MW, Hall DB, Lewis RD. Is adiposity advantageous for bone strength? A peripheral quantitative computed tomography study in late adolescent females. Am J Clin Nutr. 2007;86(5):1530-1538.
26. Ackert-Bicknell C, Beamer WG, Rosen CJ, Sundberg JP. Aging study: bone mineral density and body composition of 32 inbred strains of mice. MPD;Ackert1. Mouse Phenome Database website. http://phenome.jax.org. Accessed December 18, 2013.
27. Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A. New understanding and treatments for osteoporosis. Endocrine. 2012; 41(1):58-69.
28. Ogata N, Chikazu D, Kubota N, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J ClinInvest. 2000;105(7):935-943.
29. Cao JJ, Sun L, Gao H. Diet-induced obesity alters bone remodeling leading to decreased femoral trabecular bone mass in mice. Ann NY Acad Sci. 2010;1192:292-297.
30. Koroglu BK, Kiris F, Ersoy IH,et al. Relation of leptin, adiponectin and insulin resistance to bone mineral density in type 2 diabetic postmenopausal women. Endokrynol Pol. 2011;62(5):429-435.
31. Reid IR. Relationshipsamongbody mass, its components, and bone. Bone. 2002;31(5):547-555.
32. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes.2004;53(2):336-346.
33. Schäfer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J. 2001;15(10):1840-1842.
34. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem. 2007;102(6):1343-1357.
35. Parhami F. Possible role of oxidized lipids in osteoporosis: could hyperlipidemia be a risk factor? Prostaglandins Leukot Essent Fatty Acids. 2003;68(6):373-378.
36. Graham LS, Tintut Y, Parhami F, et al. Bone density and hyperlipidemia: the T-lymphocyte connection. J Bone Miner Res. 2010; 25(11):2460-2469.
37. Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem. 2008;283(20): 13538-13548.
38. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481(7381):314-320.
39. Lee DH, Huang H, Choi K, Mantzoros C, Kim YB. Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2012;302(5):E552-E560.
40. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8(7): 731-737.
41. Williams GA, Wang Y, Callon KE, et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology. 2009;150(8):3603-3610.
42. Kajimura D, Lee HW, Riley KJ, et al. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab. 2013;17(6):901-915.
43. Reid IR. Fat and bone. Arch Biochem Biophys. 2010;503(1):20-27.
44. Williams GA, Callon KE, Watson M, et al. Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res. 2011; 26(8):1698-1709.
45. Turner RT, Kalra SP, Wong CP, et al. Peripheral leptin regulates bone formation. J Bone Miner Res. 2013;28(1):22-34.
46. Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011;301(4):E567-E584.
47. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012; 18(3):363-374.
48. Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther. 2010;87(4):407-416.
49. Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep. 2012;10(2):101-108.
50. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11(3):234-250